Korro Bio Insider Buy‑The‑Share: COO Chappell Todd & Team Bet on RNA‑Therapy Upside
Insight: Korro Bio’s COO and top execs buy stock options—showing confidence in its RNA‑therapy pipeline and potential upside despite a volatile share price.
4 minutes to read